FBIONasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as FBIOP

Fortress Biotech, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$1.87+0.00 (0.00%)

Close on Oct 19, 2026

Market cap: $59.45M
P/E (TTM): –
Dividend yield: –

Fortress Biotech, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31	FY 2007 2007-12-31	FY 2006 2006-12-31
Cash & Equivalents	79	59	83	181	308	235	153	82	111	82	98	50	100	40	23	15	1.51	0.01	–	–
Short-Term Investments	–	–	–	–	–	–	0	18	36	0	0	20	0	–	–	–	–	–	–	–
Cash & Short-Term Investments	79	59	83	181	308	235	153	99	147	82	98	70	100	40	23	15	1.51	0.01	–	–
Receivables	30	10	15	28	23	24	14	5.50	7.76	1.83	0	–	–	–	–	–	–	–	–	–
Inventory	9.62	14	10	14	9.86	1.40	0.86	0.68	0.17	0.20	0	–	–	–	–	–	–	–	–	–
Prepaid Expenses & Other	4.90	7.11	11	9.66	7.07	6.72	4.13	6.74	5.73	9.06	1.60	0.70	0.51	0.39	0.22	0.06	–	–	–	–
Total Current Assets	124	90	117	230	346	266	156	111	183	110	100	70	100	41	23	15	–	–	–	–
Property, Plant & Equipment	2.52	3.26	6.51	13	15	12	12	12	7.12	7.38	0.31	0.05	0.45	0.05	–	0.02	–	–	–	–
Gross Property, Plant & Equipment	7.66	15	15	25	24	19	17	15	8.29	–	0.38	0.09	0.47	0.05	0.04	–	–	–	–	–
Accumulated Depreciation	-2.97	-9.93	-8.89	-12	-9.39	-6.77	-4.49	-2.56	-1.17	–	-0.07	-0.04	-0.02	0.00	-0.04	–	–	–	–	–
Long-Term Investments	–	–	–	–	0	18	11	0	1.39	1.41	2.49	4.16	0	–	–	–	–	–	–	–
Equity Method Investments	15	–	–	–	–	–	–	–	0.30	0.30	0.25	0.25	–	–	–	–	–	–	–	–
Operating Lease Right-of-Use Assets	12	14	17	20	19	20	21	0	–	–	–	–	–	–	–	–	–	–	–	–
Goodwill	–	–	–	–	–	–	–	–	19	19	0	–	–	–	–	–	–	–	–	–
Intangible Assets	28	32	20	27	13	15	7.38	1.42	0.88	17	1.25	0	–	–	–	–	–	–	–	–
Other Long-Term Assets	0.40	0.73	4.28	0.97	1.20	1.01	1.16	0.28	0.26	0.39	0.04	0.06	0.10	0.35	–	–	–	–	–	–
Total Assets	186	144	168	294	397	333	226	141	246	171	119	89	101	41	23	15	–	–	–	–
Accounts Payable	14	32	35	57	47	11	35	34	27	24	10	0.37	0.47	1.03	0.58	0.48	–	–	–	–
Accrued Expenses	47	66	74	97	91	45	25	16	18	10	8.57	3.68	4.43	2.19	2.90	1.04	–	–	–	–
Current Portion of Leases	2.13	2.62	2.52	2.45	2.10	1.85	1.78	0	–	–	–	–	–	–	–	–	–	–	–	–
Current Income Taxes Payable	0.36	0.93	0.84	0.72	0.35	0.14	0	–	–	–	–	–	–	–	–	–	–	–	–	–
Deferred Revenue (Current)	–	–	–	0.73	2.61	0	–	–	–	0	–	–	–	–	–	–	–	–	–	–
Other Current Liabilities	0.14	1.50	0.16	1.00	0	5.30	0	–	0.18	0.32	0	–	0.50	–	–	–	–	–	–	–
Total Current Liabilities	50	71	85	128	101	52	46	56	71	57	11	4.08	11	5.13	3.49	1.56	–	–	–	–
Long-Term Debt	52	58	61	92	43	52	77	60	39	23	23	14	7.02	12	–	–	–	–	–	–
Long-Term Leases	13	15	18	22	21	23	24	0	–	–	–	–	–	–	–	–	–	–	–	–
Operating Lease Liabilities	15	17	21	24	23	23	25	0	–	–	–	–	–	–	–	–	–	–	–	–
Deferred Tax Liabilities	–	–	0.23	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other Long-Term Liabilities	1.45	1.76	1.89	1.85	2.03	1.95	2.14	5.21	4.74	5.01	0.58	0.72	1.08	1.44	–	–	–	–	–	–
Total Liabilities	123	146	166	244	171	136	154	121	125	88	34	19	19	19	4.24	1.56	–	–	–	–
Total Debt	52	58	61	92	43	52	77	60	39	23	23	14	7.02	12	–	–	–	–	–	–
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0	–	–	0	–	–	–	–	–	–	–
Common Stock	0.03	0.03	0.02	0.01	0.10	0.10	0.07	0.06	0.05	0.05	0.05	0.05	0.04	0.02	0.02	0.01	–	–	–	–
Additional Paid-In Capital	784	764	717	676	656	583	462	397	364	284	247	212	203	106	76	4.31	–	–	–	–
Retained Earnings	-734	-741	-695	-634	-547	-483	-436	-396	-312	-245	-190	-142	-121	-84	-57	-20	–	–	–	–
Shareholders' Equity	50	23	23	42	109	100	26	1.85	53	38	57	71	81	22	19	-16	-16	0.01	-2.75	-0.12
Noncontrolling Interest	12	-24	-21	8.30	117	97	46	18	68	44	27	0	–	–	–	–	–	–	–	–
Total Equity	62	-1.64	1.59	50	226	197	73	20	121	83	84	71	81	22	19	-16	-16	0.01	-2.75	-0.12
Total Liabilities & Equity	186	144	168	294	397	333	226	141	246	171	119	89	101	41	23	15	–	–	–	–
Shares Outstanding(shares)	31	28	15	7.37	6.76	6.33	4.94	3.86	3.40	3.26	3.14	3.10	2.64	1.63	1.24	0.32	–	–	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 65.6%
Operating margin: -42.9%
Net margin: 163.3%
Return on equity, FY2025: 18.8%

Financial strength

Current ratio: 3.96
Debt to equity: 0.21
Debt to assets: 10.9%
Cash to current liabilities: 317.0%

Valuation

P/E ratio: –
Price to sales: 0.87
Price to book: 0.36
Dividend yield: –